Loading clinical trials...
Loading clinical trials...
A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Conditions
Interventions
Inotersen
Eplontersen
Locations
45
United States
Mayo Clinic - Arizona
Scottsdale, Arizona, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Indiana University School of Medicine - Indianapolis
Indianapolis, Indiana, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Johns Hopkins University Neurology Research Office
Baltimore, Maryland, United States
Boston University School of Medicine
Boston, Massachusetts, United States
Start Date
December 11, 2019
Primary Completion Date
April 11, 2023
Completion Date
July 12, 2023
Last Updated
December 13, 2024
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions